
    
      Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based
      on the collective clinical and nonclinical data of ziresovir.

      The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg,
      respectively.

      A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6
      subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in
      each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.
    
  